Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Intravenous Pembrolizumab and Intratumorally Injected Autologous Dendritic Cells (DCs) in Refractory Colorectal Cancer (CRC)

NCT05518032 is registered in ClinicalTrials.gov with Roswell Park Cancer Institute as lead sponsor.

NCT NCT05518032
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05518032 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Intravenous Pembrolizumab and Intratumorally Injected Autologous Dendritic Cells (DCs) in Refractory Colorectal Cancer (CRC)
Lead sponsor
Roswell Park Cancer Institute
Phase
Phase 2
Overall status
Withdrawn
Start date
October 1, 2024
Completion date
October 1, 2026
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic microsatellite stable colorectal carcinoma, recurrent colorectal carcinoma, stage iii colorectal cancer ajcc v8, stage iv colorectal cancer ajcc v8, unresectable colorectal carcinoma